GSK settles another lawsuit on heartburn drug Zantac in California
Reuters
Published Feb 29, 2024 07:24
Updated Feb 29, 2024 10:16
(Reuters) - GSK (LON:GSK) agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements made by the British drugmaker to end costly litigation.
The case, which was set to begin trial on April 2, will be dismissed. GSK does not admit to any liability in this settlement with Boyd/Steenvoord, it said on Thursday.
This follows similar Zantac settlements since June last year, including several in California. GSK still faces thousands of lawsuits in the states of California and Delaware in the U.S.
California is generally seen as a more challenging legal environment for multinational companies, as courts are known to be friendlier to plaintiffs.
The U.S. Food and Drug Administration in 2020 pulled all brands named Zantac and generic versions of the drug off the market, triggering a wave of lawsuits.
The drug, approved over four decades ago, had became the world's best selling medicine in 1988 and one of the first-ever drugs to top $1 billion in annual sales.
Analysts had estimated total settlement costs for the company of around $5 billion. GSK has not yet quantified the costs of these settlements.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.